• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The decision to stop or continue ADHD medication during breastfeeding and pregnancy is a difficult decision for women suffering from the condition. Little data exists about how long-term exposure to these medications may affect the foetus.

A study recently published in Molecular Psychiatry shows that children exposed to ADHD medication in the uterus do not develop neurological developmental disorders like impaired vision or hearing, febrile seizures, or IQ impairment. The authors acknowledge that further high-quality studies are required.

Risk/Benefit Analysis

Pregnant women who use ADHD medications must weigh the benefits of using them against the risks to the fetus. Doctors don't have enough data to provide clear recommendations but they can provide information on the risks and benefits to assist pregnant women to make an informed decision.

A study published in Molecular Psychiatry found that women who took ADHD medications during their early pregnancy did not face a significantly higher risk of fetal cardiac malformations or major structural birth defects. Researchers conducted a massive sample-based case control study to compare the incidence of structural defects that were major in infants born to mothers who took stimulants during pregnancy. Pediatric cardiologists and clinical geneticists reviewed the cases to ensure accurate case classification and to limit the chance of bias.

The study conducted by the researchers was not without limitations. Researchers were unable, in the first place to differentiate the effects of the medication from best over the counter adhd medication for adults disorder. This makes it difficult for researchers to determine whether the small associations observed among the exposed groups were due to the use of medication, or if they were confounded by co-morbidities. The researchers did not study the long-term effects for the offspring.

The study did reveal that infants whose mothers had taken ADHD medication during pregnancy were at a slightly more risk of being admitted to the neonatal intensive care unit (NICU) than those who whose mothers did not take any medication or stopped their medications before or during pregnancy. This increase was due to central nervous system-related disorders and the higher risk of admission was not found to be influenced by the stimulant medications were taken during pregnancy.

Women who took stimulant ADHD medications during pregnancy also had a higher risk of having caesarean sections or one whose baby scored low on the Apgar scale (less than 7). These increases appeared to be unrelated to the type of medication used during pregnancy.

The research suggests that the low risk associated with the use of ADHD medications during the early stages of pregnancy may be offset by the greater benefit to both the mother and child of continued treatment for the woman's condition. Physicians should discuss the issue with their patients and, where possible, help them develop strategies for improving their coping skills that can lessen the impact of her disorder on her daily life and relationships.

Medication Interactions

As more women than ever are diagnosed with ADHD and treated with medication, the question of whether or not to discontinue treatment during pregnancy is one that more and more physicians confront. These decisions are usually taken without clear and authoritative evidence. Instead, doctors have to weigh their own knowledge and experience, as well as the experiences of other doctors and the research on the subject.

The issue of risk to the infant can be particularly tricky. The research on this issue is based on observation instead of controlled studies and many of the findings are in conflict. The majority of studies focus on live births, which can underestimate the severity of teratogenic effects which can cause abortions or terminations of pregnancy. The study presented in the journal club addresses these issues, by examining both data on live and deceased births.

Conclusion Some studies have found an association between ADHD medications and certain birth defects However, other studies haven't established a link. The majority of studies show that there is a neutral, or slight negative effect. In each case, a careful evaluation of the benefits and risks is required.

It can be challenging, if not impossible, for women with ADHD to stop taking their medication. In a recent piece published in Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can increase depression and feelings of loneliness. A decrease in medication could also impact the ability to drive safely and to perform work-related tasks which are crucial aspects of normal life for people with ADHD.

She suggests that women who are not sure whether to continue taking medication or stop it due to their pregnancy, educate their family members, coworkers and acquaintances about the condition, its effects on daily functioning, and the advantages of staying on the current treatment regimen. It can also aid in ensuring that the woman feels supported as she struggles with her decision. It is important to note that some medications can pass through the placenta, so if a woman decides to discontinue her ADHD medication during pregnancy and breastfeeding, she must be aware that the effects of the drug can be transferred to the infant.

Risk of Birth Defects

As the use of ADHD medications to treat symptoms of attention deficit hyperactivity disorder (ADHD) increases there are concerns about the effects that the medications could have on fetuses. Recent research published in the journal Molecular Psychiatry has added to the body of knowledge on this issue. Researchers used two huge data sets to examine more than 4.3 million pregnancies and determine whether stimulant medications increased birth defects. Although the risk overall remains low, the researchers did find that first-trimester exposure to ADHD medicines was associated with a slightly higher rate of certain heart defects like ventriculo-septal defects (VSD).

The researchers of the study found no connection between early medication use and other congenital anomalies, such as facial clefting or club foot. The results are consistent with previous studies showing an increase, but not significant, in the risk of heart malformations among women who began taking ADHD medications prior to the time of pregnancy. This risk increased during the latter part of pregnancy, when a lot of women began to stop taking their medication.

Women who took ADHD medication during the first trimester were more likely to require a caesarean delivery or have a low Apgar after birth and have a baby that needed help breathing when they were born. However, the authors of the study were not able to eliminate bias due to selection by restricting the study to women who did not have any other medical issues that could be a contributing factor to these findings.

Researchers hope that their research will inform physicians when they meet pregnant women. The researchers advise that while discussing the risks and benefits are important, the decision regarding whether or not to stop medication should be made based on the severity of each woman's private adhd medication Cost symptoms and the needs of the woman.

The authors also warn that while discontinuing the medications is an option, it isn't a recommended practice because of the high rate of depression and other mental health issues in women who are pregnant or recently post-partum. Additionally, the research suggests that women who choose to stop taking their medication are more likely to have a difficult time adjusting to life without them after the birth of their baby.

Nursing

The responsibilities of a new mother can be overwhelming. Women with adhd medication guanfacine who have to manage their symptoms while attending doctor appointments, preparing for the arrival of a baby and adapting to new routines in the home are often faced with a number of difficulties. Many women opt to continue taking their ADHD medication during pregnancy.

The risk to breastfeeding infant is minimal because the majority of stimulant medication is absorbed through breast milk at low levels. However, the rate of exposure to medications by the infant can differ based on the dosage, frequency it is administered, and at what time it is administered. Additionally, different medications enter the baby’s system via the gastrointestinal tract or through breast milk. The impact of these medications on the health of a newborn isn't fully known.

Some doctors may decide to stop stimulant medication during a woman's pregnancy due to the lack of research. This is a difficult choice for the patient, who must balance the benefit of continuing her medication against the potential dangers to the fetus. Until more information becomes available, GPs may ask pregnant patients whether they have any background of ADHD or if they are planning to take medication in the perinatal period.

A increasing number of studies have shown that women can continue to take their ADHD medication while they are pregnant and nursing. This has led to an increasing number of patients choose to do so and in consultation with their doctor they have discovered that the benefits of continuing their current medication far exceed any risk.

It is essential for women with ADHD who are considering breastfeeding to seek a specialist psychiatrist's advice prior becoming pregnant. They should discuss their medication with their doctor as well as the pros and cons for continuing treatment. This includes non stimulant adhd medication-pharmacological strategies. Psychoeducation is also required to help women with ADHD recognize their symptoms and the root cause and learn about treatment options and reinforce existing strategies for coping. This should be a multidisciplinary approach including obstetricians, GPs, and psychiatry. Counselling for pregnancy should include the discussion of a plan for management for both the mother as well as the child, and monitoring for signs of deterioration and when necessary, making adjustments to the medication regimen.